News Releases
- Position and Policy Regarding Reduction of the Investment Unit
- Chugai Obtains Regulatory Approval for First Tablet for SMA, Evrysdi
- Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Childhood That Has not yet Become Intractable
Science and Technology
Science and Technology
Careers at Chugai
Careers at Chugai
Videos
CPR celebrates 10th Anniversary